Ysios Capital is a leading Spanish venture capital firm providing funding to highly innovative life sciences companies developing therapies for diseases with significant unmet medical needs. With offices in San Sebastián and Barcelona, the firm has a diverse team of professionals dedicated to transforming capital into medical breakthroughs, delivering both attractive financial returns and a positive societal impact.
Founded in 2008, Ysios Capital manages more than €400 million in assets across three funds. The firm also plays an active role in fostering the biotechnology ecosystem through initiatives such as InceptionBio, its new strategic vertical focused on company creation and early-stage projects. In addition, Ysios Capital serves as investment advisor to the listed Telescope Biotech Fund, which is managed by Andbank Wealth Management (https://andbank.es/boutiquehub/ysios/).
Funds:
InceptionBio – €100 million (2026): company creation and early-stage projects vertical.
Telescope Biotech Fund – FIL investment fund advised by Ysios Capital and managed by Andbank Wealth Management.
Joël Jean-Mairet, Managing Partner
Julia Salaverría, Managing Partner
Karen Wagner, Managing Partner
Joan Perelló, Managing Partner
Cristina Garmendia, General Partner
Jordi Xiol, Partner
Guillem Laporta, Partner
Arturo Urrios, Partner
Íñigo López-Huerta, CFO
Wen Wen Cheng, General Counsel and Head of ESG
Laura Argelich, Associate
Almudena Méndez, Associate
Sriram Balusu, Associate
Malgorzata Rogalska, Associate
Management of life sciences-focused venture capital funds spanning the entire investment lifecycle: company creation and technology transfer with a focus on Spain (InceptionBio), investments in startups and growth-stage companies (Ysios BioFund), and investment advisory services for the Telescope Biotech Fund, which focuses on publicly listed biotechnology companies on the Nasdaq and NYSE.
A team with deep roots in the pharmaceutical industry, supported by an extensive network of leading experts and advisors. We anticipate emerging therapeutic trends through our in-depth market insight. We are modality-agnostic, investing in small molecules, antibodies, viruses, and cell-based therapies, across both single-asset companies and technology platform businesses.
Ysios BioFund: Invests in startups and development-stage companies, primarily across Europe and the United States, with a particular focus on Spain.
InceptionBio: Focuses on company creation and technology transfer projects, with a strong emphasis on Spain.
Telescope Biotech Fund: Provides investors with exposure to publicly listed biotechnology companies on the Nasdaq and NYSE. The fund is advised by Ysios Capital and managed by Andbank Wealth Management.
Xeltis makes first commercial implant of aXess™, its vascular access device for hemodialysis
Ysios Capital
Ipsen acquires Memo Therapeutics, a portfolio company of Ysios Capital
Ysios Capital
Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development
Ysios Capital
Inbiomotion and HJ HyupJin enter a partnership for MAF Test® in South Korea
Ysios Capital
CDTI invests in the InceptionBio fund, launched by Ysios to support the creation of biotech companies
Ysios Capital
Xeltis receives CE mark for aXess™, its aXess hemodialysis conduit ™, as it moves to commercialization
Ysios Capital
Adcendo ApS Completes $75 Million Series C Financing to Continue Advancing First- and Best-in-class Clinical ADC Pipeline
Ysios Capital
Ysios Capital launches InceptionBio, a €100M fund to drive biotech company creation
Ysios Capital
Ysios Capital appoints Joan Perelló as Managing Partner and Arturo Urrios as Partner to drive a new early-stage vertical
Ysios Capital
Memo Therapeutics AG Enters into a Collaboration and Option Agreement with CSL for Development of Recombinant Polyclonal IgG Technology
Ysios Capital
